Fig. 6

The PDE1C inhibitor vinpocetine depresses cellular migration and proliferation in JMJD6-knockdown ADSCs. a Transwell migration assays show ADSCs prestained with CFSE after vinpocetine treatment. The migration capability of JMJD6-knockdown but not the JMJD6-Scr ADSCs is dramatically reduced. b The graph represents the number of migrated cells. c Intracellular levels of cAMP and cGMP increased significantly in the JMJD6-knockdown ADSCs but not in JMJD6-Scr ADSCs after treatment with the PDE1C inhibitor vinpocetine. Concentrations are expressed the means ± SD of three independent experiments. d Cell proliferation was determined according to the standard curve using a CCK8 assay; vinpocetine treatment caused a significant decrease in the proliferation rate of JMJD6-knockdown ADSCs as compared to the JMJD6-Scr ADSCs. Scale bar = 200 μm, n = 3/group, magnification = ×100, Error bars represent SD, **p < 0.01;*p < 0.05 versus the vinpocetine-treated group. ADSCs adipose-derived mesenchymal stem cells, cAMP cyclic hydrolysis both cyclic adenosine monophosphate, cGMP cyclic guanosine monophosphate, H4R3me2a histone dimethyl asymmetric H4R3, PDE1C phosphodiesterase 1C, JMJD6 Jumonji C domain-containing protein 6